Original Article
High levels of high-sensitivity C-reactive protein and uric acid can predict disease severity in patients with mitral regurgitation
Níveis elevados de proteína C-reativa de alta sensibilidade e de ácido úrico podem prever a severidade da doença em pacientes com regurgitação mitral
Lido
14423
Vezesque se leu este artigo
2048
Total PDF
12375
Total HTML
Compartilhar estatísticas
array:24 [ "pii" => "S0870255114002558" "issn" => "08702551" "doi" => "10.1016/j.repc.2014.03.014" "estado" => "S300" "fechaPublicacion" => "2014-11-01" "aid" => "540" "copyright" => "Sociedade Portuguesa de Cardiologia" "copyrightAnyo" => "2013" "documento" => "article" "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Rev Port Cardiol. 2014;33:699-706" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 6669 "formatos" => array:3 [ "EPUB" => 191 "HTML" => 5659 "PDF" => 819 ] ] "Traduccion" => array:1 [ "en" => array:19 [ "pii" => "S2174204914002645" "issn" => "21742049" "doi" => "10.1016/j.repce.2014.03.014" "estado" => "S300" "fechaPublicacion" => "2014-11-01" "aid" => "540" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "article" "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Rev Port Cardiol. 2014;33:699-706" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4053 "formatos" => array:3 [ "EPUB" => 182 "HTML" => 3301 "PDF" => 570 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "High levels of high-sensitivity C-reactive protein and uric acid can predict disease severity in patients with mitral regurgitation" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "699" "paginaFinal" => "706" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Níveis elevados de proteína C-reativa de alta sensibilidade e de ácido úrico podem prever a severidade da doença em pacientes com regurgitação mitral" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1118 "Ancho" => 1610 "Tamanyo" => 85988 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Uric acid levels according to NYHA functional class. Top of the bar represents mean and whiskers represent standard deviations. UA: uric acid.</p> <p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">P<span class="elsevierStyleInf">1</span>: NYHA I vs. NYHA II; P<span class="elsevierStyleInf">2</span>: NYHA I vs. NYHA III; P<span class="elsevierStyleInf">3</span>: NYHA I vs. NYHA IV; P<span class="elsevierStyleInf">4</span>: NYHA II vs. NYHA III; P<span class="elsevierStyleInf">5</span>: NYHA II vs. NYHA IV; P<span class="elsevierStyleInf">6</span>: NYHA III vs. NYHA IV.</p> <p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">p<span class="elsevierStyleInf">1</span>=0.029, p<span class="elsevierStyleInf">2</span>=0.010, p<span class="elsevierStyleInf">3</span><0.001, p<span class="elsevierStyleInf">4</span>=0.840, p<span class="elsevierStyleInf">5</span><0.001, p<span class="elsevierStyleInf">6</span>=0.001.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Yasin Turker, Ismail Ekinozu, Yasemin Turker, Mehmet Akkaya" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Yasin" "apellidos" => "Turker" ] 1 => array:2 [ "nombre" => "Ismail" "apellidos" => "Ekinozu" ] 2 => array:2 [ "nombre" => "Yasemin" "apellidos" => "Turker" ] 3 => array:2 [ "nombre" => "Mehmet" "apellidos" => "Akkaya" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0870255114002558" "doi" => "10.1016/j.repc.2014.03.014" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255114002558?idApp=UINPBA00004E" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204914002645?idApp=UINPBA00004E" "url" => "/21742049/0000003300000011/v1_201412120159/S2174204914002645/v1_201412120159/en/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S0870255114002601" "issn" => "08702551" "doi" => "10.1016/j.repc.2013.11.013" "estado" => "S300" "fechaPublicacion" => "2014-11-01" "aid" => "545" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "article" "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Rev Port Cardiol. 2014;33:707-15" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4198 "formatos" => array:3 [ "EPUB" => 202 "HTML" => 3222 "PDF" => 774 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "The use of reperfusion and revascularization procedures in acute coronary syndrome in Portugal: A systematic review" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "707" "paginaFinal" => "715" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Uso de procedimentos de reperfusão e revascularização na síndrome coronária aguda em Portugal: revisão sistemática" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1687 "Ancho" => 2327 "Tamanyo" => 287368 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Proportion of acute coronary syndrome patients treated with reperfusion therapies (fibrinolysis and primary PCI) in Portugal, estimated in unselected samples of patients. F: first episode; mixed ACS: mixture of patients with several types of ACS; NSTE-ACS: 90% or more patients with diagnosis of non-ST-segment elevation ACS; PCI: percutaneous coronary intervention; R: recurrent episode; STEMI: 90% or more patients with diagnosis of ST-segment elevation myocardial infarction or Q-wave myocardial infarction. * Age is presented as mean (SD) unless otherwise specified; <span class="elsevierStyleSup">†</span> mean age; <span class="elsevierStyleSup">‡</span> median age.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Luísa Lopes-Conceição, Marta Pereira, Carla Araújo, Olga Laszczýnska, Nuno Lunet, Ana Azevedo" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Luísa" "apellidos" => "Lopes-Conceição" ] 1 => array:2 [ "nombre" => "Marta" "apellidos" => "Pereira" ] 2 => array:2 [ "nombre" => "Carla" "apellidos" => "Araújo" ] 3 => array:2 [ "nombre" => "Olga" "apellidos" => "Laszczýnska" ] 4 => array:2 [ "nombre" => "Nuno" "apellidos" => "Lunet" ] 5 => array:2 [ "nombre" => "Ana" "apellidos" => "Azevedo" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2174204914002657" "doi" => "10.1016/j.repce.2013.11.012" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204914002657?idApp=UINPBA00004E" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255114002601?idApp=UINPBA00004E" "url" => "/08702551/0000003300000011/v1_201411200056/S0870255114002601/v1_201411200056/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S0870255114002546" "issn" => "08702551" "doi" => "10.1016/j.repc.2014.04.004" "estado" => "S300" "fechaPublicacion" => "2014-11-01" "aid" => "539" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "article" "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Rev Port Cardiol. 2014;33:691-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4921 "formatos" => array:3 [ "EPUB" => 205 "HTML" => 3881 "PDF" => 835 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Pro-inflammatory triggers in childhood obesity: Correlation between leptin, adiponectin and high-sensitivity C-reactive protein in a group of obese Portuguese children" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "691" "paginaFinal" => "697" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Fatores pró-inflamatórios na obesidade infantil: correlação entre a leptina, adiponectina e proteína C-reativa num grupo de crianças portuguesas obesas" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "António Pires, Paula Martins, Ana Margarida Pereira, Joana Marinho, Patrícia Vaz Silva, Margarida Marques, Eduardo Castela, Cristina Sena, Raquel Seiça" "autores" => array:9 [ 0 => array:2 [ "nombre" => "António" "apellidos" => "Pires" ] 1 => array:2 [ "nombre" => "Paula" "apellidos" => "Martins" ] 2 => array:2 [ "nombre" => "Ana Margarida" "apellidos" => "Pereira" ] 3 => array:2 [ "nombre" => "Joana" "apellidos" => "Marinho" ] 4 => array:2 [ "nombre" => "Patrícia" "apellidos" => "Vaz Silva" ] 5 => array:2 [ "nombre" => "Margarida" "apellidos" => "Marques" ] 6 => array:2 [ "nombre" => "Eduardo" "apellidos" => "Castela" ] 7 => array:2 [ "nombre" => "Cristina" "apellidos" => "Sena" ] 8 => array:2 [ "nombre" => "Raquel" "apellidos" => "Seiça" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2174204914002633" "doi" => "10.1016/j.repce.2014.04.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204914002633?idApp=UINPBA00004E" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255114002546?idApp=UINPBA00004E" "url" => "/08702551/0000003300000011/v1_201411200056/S0870255114002546/v1_201411200056/en/main.assets" ] "en" => array:19 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "High levels of high-sensitivity C-reactive protein and uric acid can predict disease severity in patients with mitral regurgitation" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "699" "paginaFinal" => "706" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Yasin Turker, Ismail Ekinozu, Yasemin Turker, Mehmet Akkaya" "autores" => array:4 [ 0 => array:4 [ "nombre" => "Yasin" "apellidos" => "Turker" "email" => array:1 [ 0 => "dryasinturker@hotmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Ismail" "apellidos" => "Ekinozu" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "Yasemin" "apellidos" => "Turker" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 3 => array:3 [ "nombre" => "Mehmet" "apellidos" => "Akkaya" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Department of Cardiology, Duzce University Faculty of Medicine, Duzce, Turkey" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Family Medicine Center, Duzce, Turkey" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Department of Cardiology, BezmiAlem University Hospital, Istanbul, Turkey" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Níveis elevados de proteína C-reativa de alta sensibilidade e de ácido úrico podem prever a severidade da doença em pacientes com regurgitação mitral" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 782 "Ancho" => 1667 "Tamanyo" => 59810 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Uric acid levels according to degree of mitral regurgitation. Top of the bar represents median and whiskers represent the 25th and 75th percentile of concentrations. UA: uric acid.</p> <p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">P<span class="elsevierStyleInf">1</span>: moderate vs. moderate to severe; P<span class="elsevierStyleInf">2</span>: moderate vs. severe; P<span class="elsevierStyleInf">3</span>: moderate to severe vs. severe.</p> <p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">p<span class="elsevierStyleInf">1</span><0.001, p<span class="elsevierStyleInf">2</span><0.001, p<span class="elsevierStyleInf">3</span>=0.123</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Primary mitral regurgitation (MR) covers all etiologies in which intrinsic lesions affect one or several components of the mitral valve apparatus.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Surgery is recommended in patients with chronic severe MR if they have any symptoms or in asymptomatic patients with left ventricular (LV) dysfunction.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> When guideline indications for surgery are reached, early surgery is associated with better outcomes, since the development of even mild symptoms by the time of surgery is associated with deleterious changes in cardiac function after surgery.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,3</span></a> However, difficulties in detecting early LV dysfunction, accurately assessing the severity of valve involvement, or recognizing early cardiac symptoms often make it difficult to determine the optimal timing of mitral valve surgery.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> In many patients, the development of symptoms is clear, but in others, symptoms are difficult to assess because of inactivity. In some patients, it may also be unclear whether symptoms are related to severe MR or to comorbidities.<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,6</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Increased levels of high-sensitivity C-reactive protein (hs-CRP) are associated with poorer functional capacity and adverse outcome in patients with LV systolic dysfunction.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> Adelaide et al. reported that CRP elevation is also associated with the presence and severity of MR and with diastolic dysfunction in acute myocardial infarction. This suggests that inflammation is related to ventricular remodeling processes, independently of LV systolic function.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> As with hs-CRP, recent findings suggest that there is also a relationship between chronic heart failure (CHF) and uric acid (UA) levels.<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9,10</span></a> Elevated serum UA levels can predict poor survival in severe and mild–moderate CHF<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9,10</span></a> and may also predict exercise intolerance and inflammatory activation.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> Nozari et al. showed that elevated UA and hs-CRP are associated with heart failure (HF) among patients with myocardial infarction (MI) and their serum levels could be a predictor for the occurrence of severe HF in patients with MI.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> In addition, Yazicioglu et al. have demonstrated that elevated serum UA in patients with dilated HF is related to severity of functional MR.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Although the association between hyperuricemia and hs-CRP with chronic heart failure has been recognized, the role of these biomarkers in MR patients is less clear. We therefore prospectively investigated the association between hs-CRP, UA and organic MR. We also assessed whether hs-CRP and UA levels are correlated with symptoms and severity of MR, LV remodeling and outcomes at one-year follow-up.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Study population</span><p id="par0020" class="elsevierStylePara elsevierViewall">A total of 200 consecutive patients with isolated and organic moderate or severe MR were included in the study. Exclusion criteria were as follows: a history of MI, previous cardiac surgery, presence of other valve disease (aortic valve disease, moderate or severe mitral stenosis, or significant right-sided organic valve disease), ischemic MR, significant liver or renal disease, chronic lung disease, malignant or hematologic disease, cardiomyopathies or pericardial diseases and concomitant inflammatory diseases such as infections and autoimmune disorders; poor echocardiographic acoustic window; and medication with hypouricemic agents. The study was carried out in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Duzce University. All subjects provided written consent.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Clinical assessment</span><p id="par0025" class="elsevierStylePara elsevierViewall">All the patients were assessed clinically and were managed and treated with standard medical therapy according to evidence-based practice guidelines. Patients were categorized according to New York Heart Association (NYHA) functional class. Clinical assessment was performed by cardiologists who were blinded to UA and hs-CRP levels.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Echocardiography</span><p id="par0030" class="elsevierStylePara elsevierViewall">In all participants, transthoracic M-mode, two-dimensional, pulsed-wave, continuous-wave and color Doppler echocardiographic examinations were performed using a General Electric Vingmed Vivid 7 (GE Vingmed Ultrasound AS, Horten, Norway) using 2.5–3.5 MHz transducers. Left ventricular end-diastolic (LVEDD) and end-systolic (LVESD) diameter and left atrial (LA) diameter were determined from two-dimensional images, according to the American Society of Echocardiography guidelines.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> Left ventricular ejection fraction (EF) was calculated using the modified Simpson's method. Severity of MR was assessed from the regurgitant fraction and vena contracta width.<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">15,16</span></a> In the case of equivocal findings between these two methods the MR score, as described by Thomas et al.,<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> was calculated from visual assessment of MR jet penetration, mitral continuous-wave Doppler characteristics, LA size, pulmonary venous flow pattern, tricuspid regurgitation velocity, and proximal isovelocity surface area radius.<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,14</span></a> Pulmonary artery systolic pressure (PAP) was calculated as the sum of the transtricuspid gradient and estimated right atrial pressure.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> The echocardiographers were blinded to patients’ symptom status and UA and hs-CRP levels.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Blood sampling</span><p id="par0035" class="elsevierStylePara elsevierViewall">Venous blood samples were drawn from the patients during a routine visit to the outpatient clinic. Whole blood count and routine biochemical tests were performed. hs-CRP was measured with chemiluminescent immunometric assay using an IMMULITE<span class="elsevierStyleSup">®</span> 1000 autoanalyzer (Siemens, Germany). Serum UA levels were assessed using a Cobas<span class="elsevierStyleSup">®</span> 6000 series autoanalyzer (Roche Diagnostics, Mannheim, Germany).</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Follow-up</span><p id="par0040" class="elsevierStylePara elsevierViewall">Clinical and echocardiographic assessments were performed at least yearly during a follow-up visit. Patients who died or underwent surgery were censored the same day, and those who remained alive were censored at the end of follow-up.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Statistical analysis</span><p id="par0045" class="elsevierStylePara elsevierViewall">The statistical analysis was performed using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA). Continuous variables are expressed as mean ± SD or median (25th–75th percentile), and categorical variables are presented as percentages and frequencies. The Student's t test and one-way ANOVA were used to compare normally distributed continuous variables in two or more groups. The Tukey test was used as a post-hoc test. The Kruskal-Wallis test was used to compare non-normally distributed continuous variables in more than two groups and the Mann-Whitney U test with Bonferroni adjustment was used for multiple comparisons. The chi-square test was used for categorical variables between two groups. Variables with a p value of <0.05 in univariate analysis were then entered into a multivariate Cox proportional hazards regression model to determine independent predictors of mortality during follow-up. Hazard ratios (HR) with 95% confidence intervals (CI) for risk factors are given. A p value of less than 0.05 was considered statistically significant.</p></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Results</span><p id="par0050" class="elsevierStylePara elsevierViewall">Of the 200 patients with moderate, moderate to severe and severe MR included in the study, 54 were asymptomatic while 146 were symptomatic. Baseline demographic, clinical characteristics and laboratory parameters of patients with MR are listed and compared between asymptomatic and symptomatic patients in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>. Mean age was significantly higher in symptomatic than in asymptomatic MR patients (p<0.05). Male gender and hypertension were more prevalent in the symptomatic group than the asymptomatic group (p<0.05 for both). Treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blocker (ARBs) and diuretics was also more prevalent in symptomatic MR patients (all p<0.05).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0055" class="elsevierStylePara elsevierViewall">Patients in the symptomatic group had lower LVEF, higher PAP, increased LVEDD and LVESD and larger LA diameter compared to the asymptomatic group (all p<0.05). Moderate to severe and severe mitral regurgitation was significantly more prevalent in the symptomatic group (p<0.001). Hemoglobin, total cholesterol, and low-density lipoprotein (LDL) cholesterol levels were significantly lower, while fasting glucose was higher, in the symptomatic group (all p<0.05).</p><p id="par0060" class="elsevierStylePara elsevierViewall">hs-CRP was significantly elevated among symptomatic MR patients compared to asymptomatic patients (5.9±6.8 vs. 2.56±1.9 mg/l; p=0.004). Median hs-CRP levels were increased significantly with increase in NYHA class (NYHA class I: 1.50 mg/l [0.90–3.50], class II: 2.73 mg/l [2.59–6.57], class III: 5.20 mg/l [3.30–9.30], and class IV: 4.07 mg/l [4.03–7.92], p<0.001; <a class="elsevierStyleCrossRef" href="#fig0005">Figure 1</a>). A similar correlation was also found with MR severity, median hs-CRP levels being significantly increased with more severe MR (moderate: 2.62 mg/l [1.70–2.95], moderate to severe: 5.20 mg/l [3.30–5.6], and severe: 5.53 mg/l [4.50–9.30], p=0.002; <a class="elsevierStyleCrossRef" href="#fig0010">Figure 2</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0065" class="elsevierStylePara elsevierViewall">UA levels were significantly elevated among symptomatic compared to asymptomatic patients (6.5±2.4 vs. 4.5±1.6 mg/dl; p<0.001). Mean UA levels increased significantly with NYHA class: 4.46±1.58 mg/dl for NYHA class I, 5.91±1.69 mg/dl for class II, 6.31±2.16 mg/dl for class III and 8.86±3.17 mg/dl for patients in class IV (p<0.001; <a class="elsevierStyleCrossRef" href="#fig0015">Figure 3</a>). Mean UA levels also increased significantly with increased severity of MR (moderate: 5.62±1.9 mg/dl, moderate to severe: 5.56±1.2 mg/dl, severe: 7.38±3.4 mg/dl, p<0.001; <a class="elsevierStyleCrossRef" href="#fig0020">Figure 4</a>). There was a significant correlation between UA level and LVEDD (r=0.40; p<0.001, <a class="elsevierStyleCrossRef" href="#fig0025">Figure 5</a>), LVESD (r=0.297; p=0.001) and LVEF (r=0.195, p=0.036), whereas hs-CRP was not correlated with these parameters.</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><elsevierMultimedia ident="fig0020"></elsevierMultimedia><elsevierMultimedia ident="fig0025"></elsevierMultimedia><p id="par0070" class="elsevierStylePara elsevierViewall">In addition, hsCRP levels were nearly significantly higher (5.5±2.5 vs. 4.2±3.6 mg/l, p=0.053), and UA levels were significantly higher (7.6±2.8 vs. 5.5±1.9 mg/dl, p<0.001) in patients who needed surgery than in those who did not according to current ESC guidelines on valvular heart disease.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">Mean follow-up was 437.1±133.9 (20–545) days. During follow-up 21 (10.5%) patients died and 26 (13%) underwent surgery. Increased UA levels were significantly associated with an increased risk of death during follow-up, along with male gender, increased serum creatinine, reduced LVEF, more severe MR and higher NYHA functional class (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>). In multivariate Cox proportional hazards analysis LVEF, NYHA class and UA levels were the only independent predictors of death (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Discussion</span><p id="par0080" class="elsevierStylePara elsevierViewall">We found a significant increase in UA and hs-CRP levels in patients with higher degrees of MR and NYHA class. We also found that increased UA level, reduced LVEF and higher NYHA class were significantly associated with an increased risk of death during follow-up.</p><p id="par0085" class="elsevierStylePara elsevierViewall">Surgery is indicated in patients who have symptoms due to chronic MR but no contraindication to surgery. The management of asymptomatic patients is controversial as there are no randomized trials to support any particular course of action.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,19</span></a> In some patients, including those who are elderly, physically inactive or obese, it is difficult to assess symptoms because of inactivity. On the other hand, in some patients, such as those with pulmonary disease, it may be unclear whether symptoms are related to severe MR or comorbidities.<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,6</span></a> Noninvasive markers that show early changes in the cardiovascular system would therefore be helpful in assessing patients with MR.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> Several studies have reported the value of elevated BNP levels to identify asymptomatic MR patients at higher risk of developing heart failure, LV dysfunction or death in mid-term follow-up.<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,20,21</span></a> A recent study showed a significant correlation between proadrenomedullin levels and degree of MR and NYHA functional class.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> It has been reported that patients with ischemic heart disease, LV systolic dysfunction and dilated cardiomyopathy with elevated hs-CRP have a worse prognosis.<a class="elsevierStyleCrossRefs" href="#bib0175"><span class="elsevierStyleSup">23,24</span></a> Two previous studies indicated that CRP predicts heart failure and death after MI.<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25,26</span></a> In our study, we found that hs-CRP levels were significantly higher among symptomatic than in asymptomatic patients. Additionally, hs-CRP levels were found to be significantly increased with higher degrees of MR and NYHA class. Hence, hs-CRP may be of value for identification of advanced stages of MR when other tools are not available or less informative. We also believe that hs-CRP may have a potential role for monitoring patient response to medication or surgery in follow-up. In agreement with our study, Arruda-Olson et al. reported that the presence of diastolic dysfunction and moderate or severe MR was associated with higher CRP levels. After further adjustment for infection within two weeks prior to MI, the association between CRP and diastolic dysfunction was no longer significant, but the association between CRP and MR remained.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> In contrast to studies in HF patients, hs-CRP was not correlated with LV dimensions or LVEF.</p><p id="par0090" class="elsevierStylePara elsevierViewall">Pathways of UA production and metabolism may have a considerable impact on CHF pathophysiology and its clinical picture.<a class="elsevierStyleCrossRefs" href="#bib0140"><span class="elsevierStyleSup">27,28</span></a> It has been shown that patients with CHF are hyperuricemic compared to controls, independently of the effects of diuretics, renal impairment and other metabolic factors.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> UA levels were significantly correlated with LV systolic and diastolic dysfunction in patients with CHF.<a class="elsevierStyleCrossRefs" href="#bib0150"><span class="elsevierStyleSup">29,30</span></a> Hyperuricemia is a constant finding in CHF, its prevalence increasing with disease severity.<a class="elsevierStyleCrossRefs" href="#bib0160"><span class="elsevierStyleSup">31,32</span></a> Elevated serum UA may itself convey prognostic information in CHF.<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">33</span></a> Anker et al. demonstrated an independent and graded relationship between serum UA levels and survival in patients with moderate to severe CHF.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> It has been shown that in patients with mild to moderate CHF, elevated serum UA levels are strongly related to death, and this relationship is independent of CHF severity and impaired renal function.<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">33</span></a> In the same study, hyperuricemia was reported to predict exercise intolerance and was a marker of inflammatory activation in CHF. Serum UA levels increased significantly in parallel with CHF severity expressed as NYHA class.<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">33</span></a> In our study, UA was significantly higher among symptomatic MR patients than in asymptomatic patients. This may help to identify asymptomatic patients in follow-up. We also found that mean UA levels increased significantly with NYHA class and higher degrees of MR. These findings suggest that UA is a potential biomarker for the assessment of therapeutic response to either medication or surgical intervention in follow-up. In agreement with previous studies in patients with heart failure, UA was significantly correlated with LVEDD, LVESD and LVEF. Therefore, we believe UA levels may be useful to assess the extent of LV remodeling and in the optimal timing of mitral valve surgery in certain subsets of patients.</p><p id="par0095" class="elsevierStylePara elsevierViewall">As a limitation of the study, we cannot rule out the impact of diuretic dose on UA.</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Conclusion</span><p id="par0100" class="elsevierStylePara elsevierViewall">UA and hs-CRP levels can help to distinguish patients with asymptomatic moderate to severe MR from symptomatic patients. UA levels may be useful to assess the extent of LV remodeling and the optimal timing of mitral valve surgery in certain subsets of patients.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Ethical disclosures</span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Protection of human and animal subjects</span><p id="par0105" class="elsevierStylePara elsevierViewall">The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Confidentiality of data</span><p id="par0110" class="elsevierStylePara elsevierViewall">The authors declare that they have followed the protocols of their work center on the publication of patient data.</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Right to privacy and informed consent</span><p id="par0115" class="elsevierStylePara elsevierViewall">The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.</p></span></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Conflicts of interest</span><p id="par0120" class="elsevierStylePara elsevierViewall">The authors have no conflicts of interest to declare.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:2 [ "identificador" => "xres384014" "titulo" => array:5 [ 0 => "Abstract" 1 => "Introduction" 2 => "Methods" 3 => "Results" 4 => "Conclusion" ] ] 1 => array:2 [ "identificador" => "xpalclavsec362879" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xres384013" "titulo" => array:5 [ 0 => "Resumo" 1 => "Introdução" 2 => "Métodos" 3 => "Resultados" 4 => "Conclusão" ] ] 3 => array:2 [ "identificador" => "xpalclavsec362878" "titulo" => "Palavras-chave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Methods" "secciones" => array:6 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Study population" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Clinical assessment" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Echocardiography" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "Blood sampling" ] 4 => array:2 [ "identificador" => "sec0035" "titulo" => "Follow-up" ] 5 => array:2 [ "identificador" => "sec0040" "titulo" => "Statistical analysis" ] ] ] 6 => array:2 [ "identificador" => "sec0045" "titulo" => "Results" ] 7 => array:2 [ "identificador" => "sec0050" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0055" "titulo" => "Conclusion" ] 9 => array:3 [ "identificador" => "sec0060" "titulo" => "Ethical disclosures" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0065" "titulo" => "Protection of human and animal subjects" ] 1 => array:2 [ "identificador" => "sec0070" "titulo" => "Confidentiality of data" ] 2 => array:2 [ "identificador" => "sec0075" "titulo" => "Right to privacy and informed consent" ] ] ] 10 => array:2 [ "identificador" => "sec0080" "titulo" => "Conflicts of interest" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2013-07-29" "fechaAceptado" => "2014-03-31" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec362879" "palabras" => array:4 [ 0 => "High-sensitivity C-reactive protein" 1 => "Mitral regurgitation" 2 => "NYHA class" 3 => "Uric acid" ] ] ] "pt" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palavras-chave" "identificador" => "xpalclavsec362878" "palabras" => array:4 [ 0 => "Proteína C-reativa de alta sensibilidade" 1 => "Regurgitação mitral" 2 => "Classe da NYHA" 3 => "Ácido úrico" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span class="elsevierStyleSectionTitle" id="sect0010">Introduction</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Both high-sensitivity CRP (hs-CRP) and uric acid (UA) levels are known to be increased in heart failure patients and are associated with poorer functional capacity and adverse outcome. The role of these markers in patients with mitral regurgitation (MR) is less clear. The aim of this study was to assess the relationship between hs-CRP, UA and organic MR. We also assessed whether hs-CRP and UA levels are correlated with symptoms of MR, severity of MR, LV remodeling and outcome during follow-up.</p> <span class="elsevierStyleSectionTitle" id="sect0015">Methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">A total of 200 consecutive patients (87 men [43.5%]; mean age 61.6±12.5 years) with moderate or severe isolated and organic MR were included in the study. All the patients were assessed clinically and were managed and treated with standard medical therapy according to evidence-based practice guidelines. Patients were categorized according to New York Heart Association (NYHA) functional class. We assessed and graded the severity of MR using a multiparametric approach. hs-CRP was measured with chemiluminescent immunometric assay using an IMMULITE<span class="elsevierStyleSup">®</span> 1000 autoanalyzer (Siemens, Germany). Serum UA levels were analyzed using a Cobas<span class="elsevierStyleSup">®</span> 6000 autoanalyzer (Roche Diagnostics, Mannheim, Germany).</p> <span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Mean UA levels increased significantly with NYHA class: 4.46±1.58 mg/dl for patients in NYHA class I, 5.91±1.69 mg/dl for class II, 6.31±2.16 mg/dl for class III and 8.86±3.17 mg/dl for class IV (p<0.001). Mean UA levels also increased significantly with increased severity of MR (moderate 5.62±1.9 mg/dl, moderate to severe 5.56±1.2 mg/dl, severe 7.38±3.4 mg/dl, p<0.001). There was a significant correlation between UA level and left ventricular end-diastolic diameter (r=0.40; p<0.001), left ventricular end-systolic diameter (r=0.297; p=0.001) and left ventricular ejection fraction (LVEF) (r=0.195, p=0.036), whereas hs-CRP was not correlated with these parameters. In multivariate Cox proportional hazards analysis LVEF, NYHA class and UA levels were the only independent predictors of death.</p> <span class="elsevierStyleSectionTitle" id="sect0025">Conclusion</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">UA and hs-CRP levels can help identify patients with asymptomatic moderate or severe mitral regurgitation. UA levels may be useful to assess the extent of left ventricular remodeling and in the optimal timing of mitral valve surgery in certain subsets of patients.</p>" ] "pt" => array:2 [ "titulo" => "Resumo" "resumen" => "<span class="elsevierStyleSectionTitle" id="sect1035">Introdução</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">É conhecido que tanto a proteína C-reativa de alta sensibilidade (PCR-as) como o ácido úrico (AU) estão elevados nos doentes com insuficiência cardíaca e, estão associados a pior capacidade funcional e a pior prognóstico. O papel destes marcadores nos doentes com regurgitação mitral (RM) é menos claro. O objetivo deste estudo foi o de avaliar a relação entre PCR-as, o AU e a RM orgânica. Também avaliamos se os níveis de PCR-as e de AU estão correlacionados com os sintomas da RM, com a severidade da RM, com a remodelagem do ventrículo esquerdo (VE) e com o prognóstico, durante o seguimento clínico.</p> <span class="elsevierStyleSectionTitle" id="sect0035">Métodos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Um total de 200 pacientes consecutivos (86 homens (43,5%); idade média 61,6±12,5 anos) com RM orgânica isolada, moderada ou severa, foram incluídos no estudo. Todos os doentes foram avaliados clinicamente e tratados com a terapêutica médica <span class="elsevierStyleItalic">standard</span> de acordo com a prática da medicina baseada na evidência e com as <span class="elsevierStyleItalic">Guidelines</span>. Os doentes foram classificados de acordo com a classe funcional da <span class="elsevierStyleItalic">New York Heart Association</span> (NYHA). Avaliamos e classificamos a gravidade da RM utilizando o modelo multiparamétrico. A PCR de alta sensibilidade foi quantificada com o teste imunométrico quemilumeniscente, usando um Autoanalizador IMMULITE<span class="elsevierStyleSup">®</span> 1000 (Siemens, Germany). Os níveis séricos de AU foram determinados usando o Autoanalizador COBAS série 6000 (Roche<span class="elsevierStyleSup">®</span> Diagnostics, Mannheim, Germany).</p> <span class="elsevierStyleSectionTitle" id="sect0040">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Os níveis médios de AU aumentaram significativamente com a classe da NYHA: 4,46±1,58 mg/dl para Classe I da NYHA, 5,91±1,69 mg/dl para a classe II da NYHA, 6,31±2,16 mg/dl para Classe III da NYHA e 8,86±3,17 mg/dl para Classe IV da NYHA (p<0,001). Os valores médios do AU também aumentaram de forma significativa com o aumento da severidade da RM (moderada=5,62±1,9 mg/dl, moderada a severa=5,56±1,2 mg/dl, severa=7.38±3.4 mg/dl, p<0.001). Foi encontrada uma correlação significativa entre os níveis de AU e o DDVE (r=0.40; p<0.001, Figure 5), DSVE (r=0,297; p=0,001) e FEVE (r=0,195, p=0,036), enquanto a PCR-as não se correlacionou com esses parâmetros. Na análise multivariável de Cox, a FEVE, a classe da NYHA e os níveis de AU foram os únicos fatores preditivos independentes de morte.</p> <span class="elsevierStyleSectionTitle" id="sect0045">Conclusão</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Os níveis de AU e de PCR-as podem ajudar a distinguir os doentes com RM moderada a severa assintomática, dos sintomáticos. Os níveis de AU podem ser úteis na determinação da extensão da remodelagem ventricular e do tempo mais adequado para a realização da cirurgia da válvula mitral, em determinados grupos de doentes.</p>" ] ] "multimedia" => array:7 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1261 "Ancho" => 2165 "Tamanyo" => 105576 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">High-sensitivity C-reactive protein levels according to NYHA functional class. Top of the bar represents median and whiskers represent the 25th and 75th percentile of concentrations. hs-CRP: high-sensitivity C-reactive protein.</p> <p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">P<span class="elsevierStyleInf">1</span>: NYHA I vs. NYHA II; P<span class="elsevierStyleInf">2</span>: NYHA I vs. NYHA III; P<span class="elsevierStyleInf">3</span>: NYHA I vs. NYHA IV; P<span class="elsevierStyleInf">4</span>: NYHA II vs. NYHA III; P<span class="elsevierStyleInf">5</span>: NYHA II vs. NYHA IV; P<span class="elsevierStyleInf">6</span>: NYHA III vs. NYHA IV.</p> <p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">p<span class="elsevierStyleInf">1</span><0.001, p<span class="elsevierStyleInf">2</span>=0.001, p<span class="elsevierStyleInf">3</span><0.001, p<span class="elsevierStyleInf">4</span>=0.008, p<span class="elsevierStyleInf">5</span>=0.062, p<span class="elsevierStyleInf">6</span>=0.794.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 991 "Ancho" => 2163 "Tamanyo" => 79963 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">High-sensitivity C-reactive protein levels according to degree of mitral regurgitation. Top of the bar represents median and whiskers represent the 25th and 75th percentile of concentrations. hs-CRP: high-sensitivity C-reactive protein.</p> <p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">P<span class="elsevierStyleInf">1</span>: moderate vs. moderate to severe; P<span class="elsevierStyleInf">2</span>: moderate vs. severe; P<span class="elsevierStyleInf">3</span>: moderate to severe vs. severe.</p> <p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">p<span class="elsevierStyleInf">1</span>=0.99, p<span class="elsevierStyleInf">2</span>=0.004, p<span class="elsevierStyleInf">3</span>=0.004.</p>" ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1124 "Ancho" => 1616 "Tamanyo" => 70400 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Uric acid levels according to NYHA functional class. Top of the bar represents mean and whiskers represent standard deviations. UA: uric acid.</p> <p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">P<span class="elsevierStyleInf">1</span>: NYHA I vs. NYHA II; P<span class="elsevierStyleInf">2</span>: NYHA I vs. NYHA III; P<span class="elsevierStyleInf">3</span>: NYHA I vs. NYHA IV; P<span class="elsevierStyleInf">4</span>: NYHA II vs. NYHA III; P<span class="elsevierStyleInf">5</span>: NYHA II vs. NYHA IV; P<span class="elsevierStyleInf">6</span>: NYHA III vs. NYHA IV.</p> <p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">p<span class="elsevierStyleInf">1</span>=0.029, p<span class="elsevierStyleInf">2</span>=0.010, p<span class="elsevierStyleInf">3</span><0.001, p<span class="elsevierStyleInf">4</span>=0.840, p<span class="elsevierStyleInf">5</span><0.001, p<span class="elsevierStyleInf">6</span>=0.001.</p>" ] ] 3 => array:7 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 782 "Ancho" => 1667 "Tamanyo" => 59810 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Uric acid levels according to degree of mitral regurgitation. Top of the bar represents median and whiskers represent the 25th and 75th percentile of concentrations. UA: uric acid.</p> <p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">P<span class="elsevierStyleInf">1</span>: moderate vs. moderate to severe; P<span class="elsevierStyleInf">2</span>: moderate vs. severe; P<span class="elsevierStyleInf">3</span>: moderate to severe vs. severe.</p> <p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">p<span class="elsevierStyleInf">1</span><0.001, p<span class="elsevierStyleInf">2</span><0.001, p<span class="elsevierStyleInf">3</span>=0.123</p>" ] ] 4 => array:7 [ "identificador" => "fig0025" "etiqueta" => "Figure 5" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr5.jpeg" "Alto" => 1736 "Ancho" => 2157 "Tamanyo" => 86637 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0105" class="elsevierStyleSimplePara elsevierViewall">Relationship of uric acid levels with left ventricular diastolic diameter in patients with isolated and organic moderate or severe MR. LVDD: left ventricular diastolic diameter; UA: uric acid.</p>" ] ] 5 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "<p id="spar0115" class="elsevierStyleSimplePara elsevierViewall">ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; BMI: body mass index; CCBs: calcium channel blockers; hs-CRP: high-sensitivity C-reactive protein; LA: left atrial diameter; LVEDD: left ventricular end-diastolic diameter; LVESD: left ventricular end-systolic diameter; PAP: pulmonary artery pressure.</p><p id="spar0120" class="elsevierStyleSimplePara elsevierViewall">Values are mean ± SD (range) or n (%).</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">All patients(n=200) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Asymptomatic(n=54) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Symptomatic(n=146) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">p \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Mean age, years</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">61.6±12.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">53.4±12.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">65.9±10.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.001</span><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">**</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Male, n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">87 (43.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14 (25.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">73 (50.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">0.002</span><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Hypertension, n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">148 (74.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">31 (57.4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">117 (80.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">0.002</span><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">**</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Smoking, n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">28 (14.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 (18.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">18 (12.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.260 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Diabetes, n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">39 (19.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 (13.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">32 (21.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.227 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">BMI (kg/m</span><span class="elsevierStyleSup"><span class="elsevierStyleItalic">2</span></span><span class="elsevierStyleItalic">)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">29.4±5.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">29.4±3.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">29.7±6.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.710 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Atrial fibrillation, n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">116 (58.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">28 (51.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">88 (61.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.257 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Echocardiographic findings</span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>LVEDD (mm) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">51.4±6.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">50.4±4.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">52.4±7.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">0.019</span><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>LVESD (mm) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">36.2±7.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">34.4±6.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">37.5±8.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">0.013</span><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>LA (mm) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">43.8±5.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">41.7±5.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">44.2±4.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">0.001</span><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">**</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Ejection fraction (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">54.1±11.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">60.2±9.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">51.0±12.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.001</span><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">**</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>PAP (mmHg) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">36.5±9.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">33.5±6.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">37.3±10.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">0.013</span><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Mitral regurgitation severity</span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Moderate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">106 (53.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">49 (90.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">57 (39.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " rowspan="3" align="char" valign="middle"><span class="elsevierStyleBold"><0.001</span><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">**</span></a></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Moderate to severe \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">60 (30.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (9.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">55 (37.7) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Severe \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">34 (17.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">34 (23.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Laboratory findings</span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Hemoglobin (g/dl) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12.7±1.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13.0±1.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12.6±1.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">0.033</span><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>BUN (mg/dl) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">18.8±7.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">17.8±6.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">19.9±9.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.123 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Serum creatinine (mg/dl) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.92±0.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.87±0.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.95±0.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.076 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Fasting glucose (mg/dl) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">113.2±42.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">98.7±12.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">104±18.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">0.023</span><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Total cholesterol (mg/dl) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">186.6±41.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">204±40 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">174±33 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.001</span><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>HDL (mg/dl) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">47.7±12.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">48.6±11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">45.3±13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.119 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>LDL (mg/dl) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">107.4±33.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">121±33 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">98±26 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.001</span><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">**</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Triglycerides (mg/dl) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">144.2±59.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">139±50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">148±65 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.372 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>hs-CRP (mg/l) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.26±6.38 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.56±1.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.9±6.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">0.004</span><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">**</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Uric acid (mg/dl) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.99±2.28 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4.5±1.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6.5±2.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.001</span><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">**</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Medication</span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Beta-blockers, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">102 (51.8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">23 (42.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">79 (55.2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.150 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>ACEIs/ARBs, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">152 (77.2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">33 (63.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">119 (83.2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">0.002</span><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">**</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Diuretics, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">97 (49.2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14 (25.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">83 (58.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.001</span><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">**</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>CCBs, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14 (7.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 (7.4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 (7.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.920 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Digoxin, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">32 (16.2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (11.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">26 (18.2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.283 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab586985.png" ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "*" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">p<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05.</p>" ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "**" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">p<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.01.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0110" class="elsevierStyleSimplePara elsevierViewall">Demographic, clinical characteristics and laboratory parameters of patients with mitral regurgitation and comparison between asymptomatic and symptomatic patients.</p>" ] ] 6 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:3 [ "leyenda" => "<p id="spar0130" class="elsevierStyleSimplePara elsevierViewall">NYHA: New York Heart Association.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Variable \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="3" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Univariate analysis</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="3" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Multivariate analysis</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">HR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">95% CI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">p \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">HR \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">95% CI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">p \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gender \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.172 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.058–0.511 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">0.002</span><a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup"><span class="elsevierStyleBold">**</span></span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.521 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.764–16.216 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.216 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NYHA class \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10.296 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.136–20.640 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.001</span><a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup"><span class="elsevierStyleBold">**</span></span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.803 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.243–11.637 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">0.019</span><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">*</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Uric acid \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.043 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.022–1.065 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.001</span><a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup"><span class="elsevierStyleBold">**</span></span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.050 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.015–1.086 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">0.005</span><a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup"><span class="elsevierStyleBold">**</span></span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Serum creatinine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7.865 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.792–22.154 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.001</span><a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup"><span class="elsevierStyleBold">**</span></span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.715 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.153–17.89 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.618 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mitral regurgitation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6.469 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.207–13.049 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.001</span><a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup"><span class="elsevierStyleBold">**</span></span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.436 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.391–5.282 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.586 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ejection fraction \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.882 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.839–0.927 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold"><0.001</span><a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup"><span class="elsevierStyleBold">**</span></span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.936 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.878–0.998 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">0.045</span><a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup"><span class="elsevierStyleBold">*</span></span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab586984.png" ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "*" "nota" => "<p class="elsevierStyleNotepara" id="npar0015">p<0.05.</p>" ] 1 => array:3 [ "identificador" => "tblfn0020" "etiqueta" => "**" "nota" => "<p class="elsevierStyleNotepara" id="npar0020">p<0.01.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0125" class="elsevierStyleSimplePara elsevierViewall">Results of univariate and multivariate Cox proportional hazard analysis of mortality in patients with mitral regurgitation.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:33 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "titulo" => "Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)" ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehu152" "Revista" => array:3 [ "tituloSerie" => "Eur Heart J" "fecha" => "2012" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24755006" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of early surgery versus conventional treatment in asymptomatic severe mitral regurgitation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "D.H. Kang" 1 => "J.H. Kim" 2 => "J.H. Rim" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/CIRCULATIONAHA.108.802314" "Revista" => array:6 [ "tituloSerie" => "Circulation" "fecha" => "2009" "volumen" => "119" "paginaInicial" => "797" "paginaFinal" => "804" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19188506" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of early surgery on survival of patients with severe mitral regurgitation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Z. Samad" 1 => "P. Kaul" 2 => "L.K. Shaw" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/hrt.2010.202432" "Revista" => array:6 [ "tituloSerie" => "Heart" "fecha" => "2011" "volumen" => "97" "paginaInicial" => "221" "paginaFinal" => "224" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21071750" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The timing of surgery for severe mitral regurgitation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J. Ross Jr." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM199611073351909" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "1996" "volumen" => "335" "paginaInicial" => "1456" "paginaFinal" => "1458" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8875925" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Plasma NT-proBNP is a potential marker of disease severity and correlates with symptoms in patients with chronic rheumatic valve disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "V. Davutoglu" 1 => "A. Celik" 2 => "M. Aksoy" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejheart.2004.07.006" "Revista" => array:6 [ "tituloSerie" => "Eur J Heart Fail" "fecha" => "2005" "volumen" => "7" "paginaInicial" => "532" "paginaFinal" => "536" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15921791" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Relation of N-terminal pro-B-type natriuretic peptide to symptoms, severity, and left ventricular remodeling in patients with organic mitral regurgitation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M. Potocki" 1 => "J. Mair" 2 => "M. Weber" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.amjcard.2009.04.023" "Revista" => array:7 [ "tituloSerie" => "Am J Cardiol" "fecha" => "2009" "volumen" => "104" "paginaInicial" => "559" "paginaFinal" => "564" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19660612" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0091674909012457" "estado" => "S300" "issn" => "00916749" ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J.D. Windram" 1 => "P.H. Loh" 2 => "A.S. Rigby" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ahj.2007.03.044" "Revista" => array:6 [ "tituloSerie" => "Am Heart J" "fecha" => "2007" "volumen" => "153" "paginaInicial" => "1048" "paginaFinal" => "1055" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17540208" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Left ventricular function and C-reactive protein levels in acute myocardial infarction" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "A.M. Arruda-Olson" 1 => "M. Enriquez-Sarano" 2 => "F. Bursi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.amjcard.2009.11.025" "Revista" => array:6 [ "tituloSerie" => "Am J Cardiol" "fecha" => "2010" "volumen" => "105" "paginaInicial" => "917" "paginaFinal" => "921" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20346306" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "F. Leyva" 1 => "S.D. Anker" 2 => "J.W. Swan" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "1997" "volumen" => "18" "paginaInicial" => "858" "paginaFinal" => "865" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9152657" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S.D. Anker" 1 => "W. Doehner" 2 => "M. Rauchhaus" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/01.CIR.0000065637.10517.A0" "Revista" => array:6 [ "tituloSerie" => "Circulation" "fecha" => "2003" "volumen" => "107" "paginaInicial" => "1991" "paginaFinal" => "1997" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12707250" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "E.A. Jankowska" 1 => "B. Ponıkowska" 2 => "J. Majda" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ijcard.2005.10.033" "Revista" => array:6 [ "tituloSerie" => "Int J Cardiol" "fecha" => "2007" "volumen" => "115" "paginaInicial" => "151" "paginaFinal" => "155" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16782216" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Correlation between the serum levels of uric acid and HS-CRP with the occurrence of early systolic failure of left ventricle following acute myocardial infarction" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Y. Nozari" 1 => "B. Geraiely" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Acta Med Iran" "fecha" => "2011" "volumen" => "49" "paginaInicial" => "531" "paginaFinal" => "535" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22009810" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Elevated uric acid and functional mitral regurgitation in dilated cardiomyopathy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M.V. Yazicioglu" 1 => "A. Avci" 2 => "G. Acar" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Eur Rev Med Pharmacol Sci" "fecha" => "2012" "volumen" => "49" "paginaInicial" => "1637" "paginaFinal" => "1641" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "R.M. Lang" 1 => "M. Bierig" 2 => "R.B. Devereux" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.echo.2005.10.005" "Revista" => array:6 [ "tituloSerie" => "J Am Soc Echocardiogr" "fecha" => "2005" "volumen" => "18" "paginaInicial" => "1440" "paginaFinal" => "1463" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16376782" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effective mitral regurgitant orifice area: clinical use and pitfalls of the proximal isovelocity surface area method" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M. Enriquez-Sarano" 1 => "F.A. Miller Jr." 2 => "S.N. Hayes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/0735-1097(94)00434-R" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "1995" "volumen" => "25" "paginaInicial" => "703" "paginaFinal" => "709" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7860917" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Assessment of mitral regurgitation severity by Doppler color flow mapping of the vena contracta" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S.A. Hall" 1 => "M.E. Brickner" 2 => "D.L. Willett" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Circulation" "fecha" => "1997" "volumen" => "95" "paginaInicial" => "636" "paginaFinal" => "642" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9024151" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The mitral regurgitation index: an echocardiographic guide to severity" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "L. Thomas" 1 => "E. Foster" 2 => "J.I. Hoffman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "1999" "volumen" => "33" "paginaInicial" => "2016" "paginaFinal" => "2022" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10362208" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M.A. Quinones" 1 => "C.M. Otto" 2 => "M. Stoddard" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Soc Echocardiogr" "fecha" => "2002" "volumen" => "15" "paginaInicial" => "167" "paginaFinal" => "184" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11836492" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Outcome of watchful waiting in asymptomatic severe mitral regurgitation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "R. Rosenhek" 1 => "F. Rader" 2 => "U. Klaar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/CIRCULATIONAHA.105.599175" "Revista" => array:6 [ "tituloSerie" => "Circulation" "fecha" => "2006" "volumen" => "113" "paginaInicial" => "2238" "paginaFinal" => "2244" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16651470" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "R. Pizarro" 1 => "O.O. Bazzino" 2 => "P.F. Oberti" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2009.06.013" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2009" "volumen" => "54" "paginaInicial" => "1099" "paginaFinal" => "1106" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19744620" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "T.M. Sutton" 1 => "R.A. Stewart" 2 => "I.L. Gerber" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2003" "volumen" => "41" "paginaInicial" => "2280" "paginaFinal" => "2287" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12821260" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A novel indicator for assessment of mitral regurgitation severity: pro-adrenomedullin" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Y. Turker" 1 => "Y. Aslantas" 2 => "Y. Turker" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ijcard.2013.04.007" "Revista" => array:6 [ "tituloSerie" => "Int J Cardiol" "fecha" => "2013" "volumen" => "168" "paginaInicial" => "2998" "paginaFinal" => "3000" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23632110" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0175" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Usefulness of C-reactive protein as an independent predictor of death in patients with ischemic cardiomyopathy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J.A. Chirinos" 1 => "J.P. Zambrano" 2 => "S. Chakko" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.amjcard.2004.08.065" "Revista" => array:6 [ "tituloSerie" => "Am J Cardiol" "fecha" => "2005" "volumen" => "95" "paginaInicial" => "88" "paginaFinal" => "90" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15619397" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "C-reactive protein in dilated cardiomyopathy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "K. Kaneko" 1 => "T. Kanda" 2 => "Y. Yamauchi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "6913" "Revista" => array:6 [ "tituloSerie" => "Cardiology" "fecha" => "1999" "volumen" => "91" "paginaInicial" => "215" "paginaFinal" => "219" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10545675" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M. Suleiman" 1 => "D. Aronson" 2 => "S.A. Reisner" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Am J Med" "fecha" => "2003" "volumen" => "115" "paginaInicial" => "695" "paginaFinal" => "701" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14693321" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0091674901659451" "estado" => "S300" "issn" => "00916749" ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M. Suleiman" 1 => "R. Khatib" 2 => "Y. Agmon" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2005.10.055" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2006" "volumen" => "47" "paginaInicial" => "962" "paginaFinal" => "968" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16516078" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0140" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Uric acid in chronic heart failure" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "W. Doehner" 1 => "S.D. Anker" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Semin Nephrol" "fecha" => "2005" "volumen" => "25" "paginaInicial" => "61" "paginaFinal" => "66" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15660337" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0145" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.H. Hare" 1 => "R.J. Johnson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/01.CIR.0000066420.36123.35" "Revista" => array:6 [ "tituloSerie" => "Circulation" "fecha" => "2003" "volumen" => "107" "paginaInicial" => "1951" "paginaFinal" => "1953" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12707249" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0150" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients with congestive heart failure" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "H. Sakai" 1 => "T. Tsutamoto" 2 => "T. Tsutsui" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Circ J" "fecha" => "2006" "volumen" => "70" "paginaInicial" => "1006" "paginaFinal" => "1011" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16864933" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0155" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M. Cicoira" 1 => "L. Zanolla" 2 => "A. Rossi" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am Heart J" "fecha" => "2002" "volumen" => "143" "paginaInicial" => "1107" "paginaFinal" => "1111" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12075270" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0160" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Uric acid in cachectic and non-cachectic CHF patients – relation to leg vascular resistance" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "W. Doehner" 1 => "M. Rauchhaus" 2 => "V.G. Florea" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1067/mhj.2001.114367" "Revista" => array:6 [ "tituloSerie" => "Am Heart J" "fecha" => "2001" "volumen" => "141" "paginaInicial" => "792" "paginaFinal" => "799" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11320368" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0165" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Uric acid in chronic heart failure: a measure of anaerobic threshold" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "F. Leyva" 1 => "T.P. Chua" 2 => "S.D. Anker" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Metabolism" "fecha" => "1998" "volumen" => "47" "paginaInicial" => "1156" "paginaFinal" => "1159" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9751248" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0170" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "E.A. Jankowska" 1 => "B. Ponikowska" 2 => "J. Majda" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ijcard.2005.10.033" "Revista" => array:6 [ "tituloSerie" => "Int J Cardiol" "fecha" => "2007" "volumen" => "115" "paginaInicial" => "151" "paginaFinal" => "155" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16782216" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/08702551/0000003300000011/v1_201411200056/S0870255114002558/v1_201411200056/en/main.assets" "Apartado" => array:4 [ "identificador" => "358" "tipo" => "SECCION" "pt" => array:2 [ "titulo" => "Artigos originais" "idiomaDefecto" => true ] "idiomaDefecto" => "pt" ] "PDF" => "https://static.elsevier.es/multimedia/08702551/0000003300000011/v1_201411200056/S0870255114002558/v1_201411200056/en/main.pdf?idApp=UINPBA00004E&text.app=https://revportcardiol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255114002558?idApp=UINPBA00004E" ]
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2024 Novembro | 14 | 4 | 18 |
| 2024 Outubro | 120 | 27 | 147 |
| 2024 Setembro | 161 | 22 | 183 |
| 2024 Agosto | 150 | 33 | 183 |
| 2024 Julho | 148 | 40 | 188 |
| 2024 Junho | 81 | 26 | 107 |
| 2024 Maio | 91 | 30 | 121 |
| 2024 Abril | 79 | 25 | 104 |
| 2024 Maro | 93 | 20 | 113 |
| 2024 Fevereiro | 94 | 29 | 123 |
| 2024 Janeiro | 79 | 30 | 109 |
| 2023 Dezembro | 102 | 25 | 127 |
| 2023 Novembro | 112 | 25 | 137 |
| 2023 Outubro | 81 | 26 | 107 |
| 2023 Setembro | 80 | 22 | 102 |
| 2023 Agosto | 72 | 19 | 91 |
| 2023 Julho | 96 | 11 | 107 |
| 2023 Junho | 94 | 15 | 109 |
| 2023 Maio | 90 | 20 | 110 |
| 2023 Abril | 94 | 5 | 99 |
| 2023 Maro | 92 | 16 | 108 |
| 2023 Fevereiro | 82 | 23 | 105 |
| 2023 Janeiro | 79 | 5 | 84 |
| 2022 Dezembro | 90 | 19 | 109 |
| 2022 Novembro | 97 | 22 | 119 |
| 2022 Outubro | 118 | 21 | 139 |
| 2022 Setembro | 117 | 24 | 141 |
| 2022 Agosto | 132 | 33 | 165 |
| 2022 Julho | 134 | 40 | 174 |
| 2022 Junho | 102 | 19 | 121 |
| 2022 Maio | 98 | 27 | 125 |
| 2022 Abril | 97 | 23 | 120 |
| 2022 Maro | 93 | 27 | 120 |
| 2022 Fevereiro | 110 | 25 | 135 |
| 2022 Janeiro | 120 | 23 | 143 |
| 2021 Dezembro | 77 | 28 | 105 |
| 2021 Novembro | 81 | 36 | 117 |
| 2021 Outubro | 95 | 33 | 128 |
| 2021 Setembro | 113 | 28 | 141 |
| 2021 Agosto | 121 | 26 | 147 |
| 2021 Julho | 133 | 29 | 162 |
| 2021 Junho | 125 | 24 | 149 |
| 2021 Maio | 178 | 28 | 206 |
| 2021 Abril | 340 | 63 | 403 |
| 2021 Maro | 200 | 14 | 214 |
| 2021 Fevereiro | 140 | 18 | 158 |
| 2021 Janeiro | 142 | 10 | 152 |
| 2020 Dezembro | 102 | 12 | 114 |
| 2020 Novembro | 108 | 11 | 119 |
| 2020 Outubro | 124 | 8 | 132 |
| 2020 Setembro | 180 | 12 | 192 |
| 2020 Agosto | 194 | 3 | 197 |
| 2020 Julho | 133 | 14 | 147 |
| 2020 Junho | 139 | 8 | 147 |
| 2020 Maio | 136 | 5 | 141 |
| 2020 Abril | 121 | 5 | 126 |
| 2020 Maro | 183 | 9 | 192 |
| 2020 Fevereiro | 291 | 30 | 321 |
| 2020 Janeiro | 117 | 8 | 125 |
| 2019 Dezembro | 113 | 10 | 123 |
| 2019 Novembro | 76 | 4 | 80 |
| 2019 Outubro | 122 | 4 | 126 |
| 2019 Setembro | 275 | 15 | 290 |
| 2019 Agosto | 155 | 18 | 173 |
| 2019 Julho | 143 | 9 | 152 |
| 2019 Junho | 153 | 15 | 168 |
| 2019 Maio | 151 | 6 | 157 |
| 2019 Abril | 150 | 20 | 170 |
| 2019 Maro | 165 | 15 | 180 |
| 2019 Fevereiro | 135 | 14 | 149 |
| 2019 Janeiro | 108 | 6 | 114 |
| 2018 Dezembro | 127 | 10 | 137 |
| 2018 Novembro | 198 | 13 | 211 |
| 2018 Outubro | 453 | 35 | 488 |
| 2018 Setembro | 80 | 10 | 90 |
| 2018 Agosto | 82 | 14 | 96 |
| 2018 Julho | 49 | 9 | 58 |
| 2018 Junho | 77 | 4 | 81 |
| 2018 Maio | 78 | 16 | 94 |
| 2018 Abril | 67 | 7 | 74 |
| 2018 Maro | 77 | 11 | 88 |
| 2018 Fevereiro | 72 | 13 | 85 |
| 2018 Janeiro | 46 | 4 | 50 |
| 2017 Dezembro | 103 | 13 | 116 |
| 2017 Novembro | 63 | 7 | 70 |
| 2017 Outubro | 62 | 10 | 72 |
| 2017 Setembro | 51 | 9 | 60 |
| 2017 Agosto | 60 | 10 | 70 |
| 2017 Julho | 58 | 12 | 70 |
| 2017 Junho | 73 | 17 | 90 |
| 2017 Maio | 112 | 11 | 123 |
| 2017 Abril | 50 | 9 | 59 |
| 2017 Maro | 57 | 33 | 90 |
| 2017 Fevereiro | 88 | 10 | 98 |
| 2017 Janeiro | 23 | 6 | 29 |
| 2016 Dezembro | 20 | 10 | 30 |
| 2016 Novembro | 61 | 6 | 67 |
| 2016 Outubro | 45 | 3 | 48 |
| 2016 Setembro | 74 | 7 | 81 |
| 2016 Agosto | 13 | 2 | 15 |
| 2016 Julho | 9 | 4 | 13 |
| 2016 Junho | 20 | 0 | 20 |
| 2016 Maio | 8 | 5 | 13 |
| 2016 Abril | 38 | 2 | 40 |
| 2016 Maro | 67 | 17 | 84 |
| 2016 Fevereiro | 108 | 27 | 135 |
| 2016 Janeiro | 70 | 15 | 85 |
| 2015 Dezembro | 80 | 13 | 93 |
| 2015 Novembro | 75 | 16 | 91 |
| 2015 Outubro | 69 | 22 | 91 |
| 2015 Setembro | 63 | 15 | 78 |
| 2015 Agosto | 63 | 13 | 76 |
| 2015 Julho | 50 | 9 | 59 |
| 2015 Junho | 49 | 4 | 53 |
| 2015 Maio | 36 | 10 | 46 |
| 2015 Abril | 46 | 15 | 61 |
| 2015 Maro | 46 | 12 | 58 |
| 2015 Fevereiro | 50 | 19 | 69 |
| 2015 Janeiro | 53 | 23 | 76 |
| 2014 Dezembro | 102 | 66 | 168 |
| 2014 Novembro | 43 | 21 | 64 |
Mostrar tudo
